Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity

References

• 1  Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the Hsp90/Hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood)228(2),111–133 (2003).
  Medline CASGoogle Scholar
• 2  Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res.18(1),64–76 (2012).
  Medline CASGoogle Scholar
• 3  Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets3(5),301–323 (2003).
  Medline CASGoogle Scholar
• 4  Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell89(2),239–250 (1997).
  Medline CASGoogle Scholar
• 5  Roe SM, Prodromou C, O‘Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem.42(2),260–266 (1999).
  Medline CASGoogle Scholar
• 6  Richter K, Hendershot LM, Freeman BC. The cellular world according to Hsp90. Nat. Struct. Mol. Biol.14(2),90–94 (2007).
  Medline CASGoogle Scholar
• 7  Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta1823(3),624–635 (2012).
  Medline CASGoogle Scholar
• 8  Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta1823(3),648–655 (2012).
  Medline CASGoogle Scholar
• 9  Johnson JL. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim. Biophys. Acta1823(3),607–613 (2012).
  Medline CASGoogle Scholar
• 10  Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer10(8),537–549 (2010).
  Medline CASGoogle Scholar
• 11  Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer5(10),761–772 (2005).
  Medline CASGoogle Scholar
• 12  Grad I, Cederroth CR, Walicki J et al. The molecular chaperone Hsp90alpha is required for meiotic progression of spermatocytes beyond pachytene in the mouse. PLoS ONE5(12),e15770 (2010).
  Medline CASGoogle Scholar
• 13  Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol.11(7),515–528 (2010).
  Medline CASGoogle Scholar
• 14  Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci.59(10),1640–1648 (2002).
  Medline CASGoogle Scholar
• 15  Ali MM, Roe SM, Vaughan CK et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature440(7087),1013–1017 (2006).
  Medline CASGoogle Scholar
• 16  Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94–nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell28(1),41–56 (2007).
  Medline CASGoogle Scholar
• 17  Graf C, Stankiewicz M, Kramer G, Mayer MP. Spatially and kinetically resolved changes in the conformational dynamics of the Hsp90 chaperone machine. EMBO J.28(5),602–613 (2009).
  Medline CASGoogle Scholar
• 18  Hessling M, Richter K, Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol.16(3),287–293 (2009).
  Medline CASGoogle Scholar
• 19  Mickler M, Hessling M, Ratzke C, Buchner J, Hugel T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nat. Struct. Mol. Biol.16(3),281–286 (2009).
  Medline CASGoogle Scholar
• 20  Neckers L, Mollapour M, Tsutsumi S. The complex dance of the molecular chaperone Hsp90. Trends Biochem. Sci.34(5),223–226 (2009).
  Medline CASGoogle Scholar
• 21  Shiau AK, Harris SF, Southworth DR, Agard DA. Structural analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell127(2),329–340 (2006).
  Medline CASGoogle Scholar
• 22  Vaughan CK, Gohlke U, Sobott F et al. Structure of an Hsp90–Cdc37–Cdk4 complex. Mol. Cell23(5),697–707 (2006).
  Medline CASGoogle Scholar
• 23  Jackson SE. Hsp90: structure and function. Top. Curr. Chem.328,155–240 (2013).
  Medline CASGoogle Scholar
• 24  Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem.75,271–294 (2006).
  Medline CASGoogle Scholar
• 25  Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. (172),259–277 (2006).
  MedlineGoogle Scholar
• 26  Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim. Biophys. Acta1823(3),756–766 (2012).
  Medline CASGoogle Scholar
• 27  Alarcon SV, Mollapour M, Lee MJ et al. Tumor-intrinsic and tumor-extrinsic factors impacting Hsp90-targeted therapy. Curr. Mol. Med.12(9),1125–1141 (2012).
  Medline CASGoogle Scholar
• 28  Modi S, Stopeck A, Linden H et al. Hsp90 inhibition is effective in breast cancer: a Phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res.17(15),5132–5139 (2011).
  Medline CASGoogle Scholar
• 29  Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (Hsp90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol.152(4),367–379 (2011).
  Medline CASGoogle Scholar
• 30  Roue G, Perez-Galan P, Mozos A et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood117(4),1270–1279 (2011).
  Medline CASGoogle Scholar
• 31  Scaltriti M, Serra V, Normant E et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol. Cancer Ther.10(5),817–824 (2011).
  Medline CASGoogle Scholar
• 32  Schulte TW, Akinaga S, Soga S et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones3(2),100–108 (1998).
  Medline CASGoogle Scholar
• 33  Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, Hsp90, by the transformation suppressing agent, radicicol. Oncogene16(20),2639–2645 (1998).
  Medline CASGoogle Scholar
• 34  Jensen MR, Schoepfer J, Radimerski T et al. NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res.10(2),R33 (2008).
  MedlineGoogle Scholar
• 35  Moser C, Lang SA, Hackl C et al. Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res.32(7),2551–2561 (2012).
  Medline CASGoogle Scholar
• 36  Nagengast WB, De Korte MA, Oude Munnink TH et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922. J. Nucl. Med.51(5),761–767 (2010).
  Medline CASGoogle Scholar
• 37  Ishii T, Seike T, Nakashima T et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J.2(4),e68 (2012).
  Medline CASGoogle Scholar
• 38  Woodhead AJ, Angove H, Carr MG et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem.53(16),5956–5969 (2010).
  Medline CASGoogle Scholar
• 39  Chiosis G, Timaul MN, Lucas B et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol.8(3),289–299 (2001).
  Medline CASGoogle Scholar
• 40  Wright L, Barril X, Dymock B et al. Structure–activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem. Biol.11(6),775–785 (2004).
  Medline CASGoogle Scholar
• 41  Caldas-Lopes E, Cerchietti L, Ahn JH et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA106(20),8368–8373 (2009).
  Medline CASGoogle Scholar
• 42  Cheung KM, Matthews TP, James K et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett.15(14),3338–3343 (2005).
  Medline CASGoogle Scholar
• 43  Eccles SA, Massey A, Raynaud FI et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res.68(8),2850–2860 (2008).
  Medline CASGoogle Scholar
• 44  Nakashima T, Ishii T, Tagaya H et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin. Cancer Res.16(10),2792–2802 (2010).
  Medline CASGoogle Scholar
• 45  Mccleese JK, Bear MD, Fossey SL et al. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer125(12),2792–2801 (2009).
  Medline CASGoogle Scholar
• 46  Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem.275(47),37181–37186 (2000).
  Medline CASGoogle Scholar
• 47  Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl Cancer Inst.92(3),242–248 (2000).
  Medline CASGoogle Scholar
• 48  Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem.15(26),2702–2717 (2008).
  Medline CASGoogle Scholar
• 49  Conde R, Belak ZR, Nair M, O‘Carroll RF, Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem. Cell Biol.87(6),845–851 (2009).
  Medline CASGoogle Scholar
• 50  Matts RL, Brandt GE, Lu Y et al. A systematic protocol for the characterization of Hsp90 modulators. Bioorg. Med. Chem.19(1),684–692 (2011).
  Medline CASGoogle Scholar
• 51  Shelton SN, Shawgo ME, Matthews SB et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol.76(6),1314–1322 (2009).
  Medline CASGoogle Scholar
• 52  Caplan AJ. What is a co-chaperone? Cell Stress Chaperones8(2),105–107 (2003).
  MedlineGoogle Scholar
• 53  Abbas-Terki T, Briand PA, Donze O, Picard D. The Hsp90 co-chaperones Cdc37 and Sti1 interact physically and genetically. Biol. Chem.383(9),1335–1342 (2002).
  Medline CASGoogle Scholar
• 54  Chang HC, Nathan DF, Lindquist S. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol. Cell. Biol.17(1),318–325 (1997).
  Medline CASGoogle Scholar
• 55  Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J. Biol. Chem.278(12),10328–10333 (2003).
  Medline CASGoogle Scholar
• 56  Song Y, Masison DC. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1). J. Biol. Chem.280(40),34178–34185 (2005).
  Medline CASGoogle Scholar
• 57  Lee P, Shabbir A, Cardozo C, Caplan AJ. Sti1 and Cdc37 can stabilize Hsp90 in chaperone complexes with a protein kinase. Mol. Biol. Cell15(4),1785–1792 (2004).
  Medline CASGoogle Scholar
• 58  Maclean M, Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones8(2),114–119 (2003).
  Medline CASGoogle Scholar
• 59  Siligardi G, Panaretou B, Meyer P et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem.277(23),20151–20159 (2002).
  Medline CASGoogle Scholar
• 60  Vaughan CK, Mollapour M, Smith JR et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell.31(6),886–895 (2008).
  Medline CASGoogle Scholar
• 61  Mclaughlin SH, Sobott F, Yao ZP et al. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol.356(3),746–758 (2006).
  Medline CASGoogle Scholar
• 62  Picard D. Intracellular dynamics of the Hsp90 co-chaperone p23 is dictated by Hsp90. Exp. Cell. Res.312(2),198–204 (2006).
  Medline CASGoogle Scholar
• 63  Sullivan WP, Owen BA, Toft DO. The influence of ATP and p23 on the conformation of Hsp90. J. Biol. Chem.277(48),45942–45948 (2002).
  Medline CASGoogle Scholar
• 64  Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J. Biol. Chem.278(19),17228–17235 (2003).
  Medline CASGoogle Scholar
• 65  Meyer P, Prodromou C, Liao C et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J.23(3),511–519 (2004).
  Medline CASGoogle Scholar
• 66  Panaretou B, Siligardi G, Meyer P et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone aha1. Mol. Cell.10(6),1307–1318 (2002).
  Medline CASGoogle Scholar
• 67  Johnson JL, Halas A, Flom G. Nucleotide-dependent interaction of Saccharomyces cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1. Mol. Cell. Biol.27(2),768–776 (2007).
  Medline CASGoogle Scholar
• 68  Mayr C, Richter K, Lilie H, Buchner J. Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties. J. Biol. Chem.275(44),34140–34146 (2000).
  Medline CASGoogle Scholar
• 69  Catlett MG, Kaplan KB. Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p. J. Biol. Chem.281(44),33739–33748 (2006).
  Medline CASGoogle Scholar
• 70  Caplan AJ, Mandal AK, Theodoraki MA. Molecular chaperones and protein kinase quality control. Trends Cell. Biol.17(2),87–92 (2007).
  Medline CASGoogle Scholar
• 71  Zhang M, Boter M, Li K et al. Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J.27(20),2789–2798 (2008).
  Medline CASGoogle Scholar
• 72  Millson SH, Nuttall JM, Mollapour M, Piper PW. The Hsp90/Cdc37p chaperone system is a determinant of molybdate resistance in Saccharomyces cerevisiae. Yeast26(6),339–347 (2009).
  Medline CASGoogle Scholar
• 73  Vaughan CK, Piper PW, Pearl LH, Prodromou C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic Hsp90s. FEBS J.276(1),199–209 (2009).
  Medline CASGoogle Scholar
• 74  Forafonov F, Toogun OA, Grad I, Suslova E, Freeman BC, Picard D. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol. Cell. Biol.28(10),3446–3456 (2008).
  Medline CASGoogle Scholar
• 75  Johnson JL, Brown C. Plasticity of the Hsp90 chaperone machine in divergent eukaryotic organisms. Cell Stress Chaperones14(1),83–94 (2009).
  Medline CASGoogle Scholar
• 76  Roe SM, Ali MM, Meyer P et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell116(1),87–98 (2004).
  Medline CASGoogle Scholar
• 77  Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem.279(50),51989–51998 (2004).
  Medline CASGoogle Scholar
• 78  Gray PJ Jr, Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res.67(24),11942–11950 (2007).
  Medline CASGoogle Scholar
• 79  Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone Cdc37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors. Oncogene28(2),157–169 (2009).
  Medline CASGoogle Scholar
• 80  Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J. Biol. Chem.284(51),35381–35389 (2009).
  Medline CASGoogle Scholar
• 81  Bandhakavi S, Mccann RO, Hanna DE, Glover CV. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J. Biol. Chem.278(5),2829–2836 (2003).
  Medline CASGoogle Scholar
• 82  Miyata Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell. Mol. Life Sci.66(11–12),1840–1849 (2009).
  Medline CASGoogle Scholar
• 83  Shao J, Prince T, Hartson SD, Matts RL. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem.278(40),38117–38120 (2003).
  Medline CASGoogle Scholar
• 84  Xu W, Mollapour M, Prodromou C et al. Dynamic tyrosine phosphorylation modulates cycling of the Hsp90-P50(Cdc37)-AHA1 chaperone machine. Mol. Cell.47(3),434–443 (2012).
  Medline CASGoogle Scholar
• 85  Retzlaff M, Hagn F, Mitschke L et al. Asymmetric activation of the Hsp90 dimer by its cochaperone aha1. Mol. Cell37(3),344–354 (2010).
  Medline CASGoogle Scholar
• 86  Wang X, Venable J, Lapointe P et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell127(4),803–815 (2006).
  Medline CASGoogle Scholar
• 87  Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of Hsp90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res.68(4),1188–1197 (2008).
  MedlineGoogle Scholar
• 88  Richter K, Walter S, Buchner J. The co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J Mol Biol342(5),1403–1413 (2004).
  Medline CASGoogle Scholar
• 89  Johnson JL, Toft DO. Binding of p23 and Hsp90 during assembly with the progesterone receptor. Mol. Endocrinol.9(6),670–678 (1995).
  Medline CASGoogle Scholar
• 90  Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin. Oncol.33(4),457–465 (2006).
  Medline CASGoogle Scholar
• 91  Onuoha SC, Coulstock ET, Grossmann JG, Jackson SE. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol.379(4),732–744 (2008).
  Medline CASGoogle Scholar
• 92  Schmid AB, Lagleder S, Grawert MA et al. The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J.31(6),1506–1517 (2012).
  Medline CASGoogle Scholar
• 93  Li J, Richter K, Buchner J. Mixed Hsp90-cochaperone complexes are important for the progression of the reaction cycle. Nat. Struct. Mol. Biol.18(1),61–66 (2011).
  MedlineGoogle Scholar
• 94  Piper PW, Panaretou B, Millson SH et al. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors. Gene302(1–2),165–170 (2003).
  Medline CASGoogle Scholar
• 95  Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol. Cell. Biol.9(9),3919–3930 (1989).
  Medline CASGoogle Scholar
• 96  Millson SH, Vaughan CK, Zhai C et al. Chaperone ligand-discrimination by the TPR-domain protein Tah1. Biochem. J.413(2),261–268 (2008).
  Medline CASGoogle Scholar
• 97  Prodromou C, Siligardi G, O‘Brien R et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J.18(3),754–762 (1999).
  Medline CASGoogle Scholar
• 98  Zuehlke AD, Johnson JL. Chaperoning the chaperone: a role for the co-chaperone Cpr7 in modulating Hsp90 function in Saccharomyces cerevisiae. Genetics191(3),805–814 (2012).
  Medline CASGoogle Scholar
• 99  Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat. Struct. Mol. Biol.20(3),326–331 (2013).
  Medline CASGoogle Scholar
• 100  Dolinski KJ, Cardenas ME, Heitman J. CNS1 encodes an essential p60/Sti1 homolog in Saccharomyces cerevisiae that suppresses cyclophilin 40 mutations and interacts with Hsp90. Mol. Cell. Biol.18(12),7344–7352 (1998).
  Medline CASGoogle Scholar
• 101  Goes FS, Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur. J. Biochem.268(8),2281–2289 (2001).
  Medline CASGoogle Scholar
• 102  Mollapour M, Tsutsumi S, Donnelly AC et al. Swe1 Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell.37(3),333–343 (2010).
  Medline CASGoogle Scholar
• 103  Iwai A, Bourboulia D, Mollapour M et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle11(19),3649–3655 (2012).
  Medline CASGoogle Scholar
• 104  Scroggins BT, Neckers L. Post-translational modification of heat shock protein 90: impact on chaperone function. Expert Opin. Drug Discov.2(10),1403–1414 (2007).
  Medline CASGoogle Scholar
• 105  Yang Y, Rao R, Shen J et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res.68(12),4833–4842 (2008).
  Medline CASGoogle Scholar
• 106  Rao R, Fiskus W, Yang Y et al. HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood112(5),1886–1893 (2008).
  Medline CASGoogle Scholar
• 107  Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget2(5),407–417 (2011).
  MedlineGoogle Scholar
• 108  Mimnaugh EG, Worland PJ, Whitesell L, Neckers LM. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the Hsp90 stress protein and the p60v-src tyrosine kinase. J. Biol. Chem.270(48),28654–28659 (1995).
  Medline CASGoogle Scholar
• 109  Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J.25(2),367–376 (2006).
  Medline CASGoogle Scholar
• 110  Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle8(13),2050–2056 (2009).
  Medline CASGoogle Scholar
• 111  Mollapour M, Tsutsumi S, Truman AW et al. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol. Cell41(6),672–681 (2011).
  Medline CASGoogle Scholar
• 112  Prodromou C, Panaretou B, Chohan S et al. The ATPase cycle of Hsp90 drives a molecular ‘clamp‘ via transient dimerization of the N-terminal domains. EMBO J.19(16),4383–4392 (2000).
  Medline CASGoogle Scholar
• 113  Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP, Obermann WM. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell. Biol.26(22),8385–8395 (2006).
  Medline CASGoogle Scholar
• 114  Nathan DF, Lindquist S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell. Biol.15(7),3917–3925 (1995).
  Medline CASGoogle Scholar
• 115  Cunningham CN, Krukenberg KA, Agard DA. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol. Chem.283(30),21170–21178 (2008).
  Medline CASGoogle Scholar
• 116  Mollapour M, Neckers L. Detecting Hsp90 phosphorylation. Methods Mol. Biol.787,67–74 (2011).
  Medline CASGoogle Scholar
• 117  Duval M, Le Boeuf F, Huot J, Gratton JP. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell18(11),4659–4668 (2007).
  Medline CASGoogle Scholar
• 118  Mollapour M, Tsutsumi S, Neckers L. Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle9(12),2310–2316 (2010).
  Medline CASGoogle Scholar
• 119  Scroggins BT, Robzyk K, Wang D et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell25(1),151–159 (2007).
  Medline CASGoogle Scholar
• 120  Robbins N, Leach MD, Cowen LE. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance. Cell Rep.2(4),878–888 (2012).
  Medline CASGoogle Scholar
• 121  Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst.94(7),504–513 (2002).
  Medline CASGoogle Scholar
• 122  Park JH, Kim SH, Choi MC et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun.368(2),318–322 (2008).
  Medline CASGoogle Scholar
• 123  Bali P, Pranpat M, Bradner J et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem.280(29),26729–26734 (2005).
  Medline CASGoogle Scholar
• 124  Kovacs JJ, Murphy PJ, Gaillard S et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell18(5),601–607 (2005).
  Medline CASGoogle Scholar
• 125  Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem.284(12),7436–7445 (2009).
  Medline CASGoogle Scholar
• 126  Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB. Regulation of the dynamics of Hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem.280(40),33792–33799 (2005).
  Medline CASGoogle Scholar
• 127  Ai J, Wang Y, Dar JA et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinol.23(12),1963–1972 (2009).
  Medline CASGoogle Scholar
• 128  Millson SH, Chua CS, Roe SM et al. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90. FASEB J.25(11),3828–3837 (2011).
  Medline CASGoogle Scholar
• 129  Millson SH, Prodromou C, Piper PW. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta. Biochem. Pharmacol.79(11),1581–1588 (2010).
  Medline CASGoogle Scholar
• 130  Zurawska A, Urbanski J, Matuliene J et al. Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim. Biophys. Acta1803(5),575–583 (2010).
  Medline CASGoogle Scholar
• 131  Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature425(6956),407–410 (2003).
  Medline CASGoogle Scholar
• 132  Armstrong H, Wolmarans A, Mercier R, Mai B, Lapointe P. The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922. PLoS ONE7(11),e49322 (2012).
  Medline CASGoogle Scholar
• 133  Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst.91(22),1940–1949 (1999).
  Medline CASGoogle Scholar
• 134  Gaspar N, Sharp SY, Pacey S et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res.69(5),1966–1975 (2009).
  Medline CASGoogle Scholar
• 135  Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. Mol. Pharmacol.46(4),677–684 (1994).
  Medline CASGoogle Scholar
• 136  Mccollum AK, Teneyck CJ, Stensgard B et al. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res.68(18),7419–7427 (2008).
  Medline CASGoogle Scholar
• 137  Guo F, Rocha K, Bali P et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res.65(22),10536–10544 (2005).
  Medline CASGoogle Scholar
• 138  Powers MV, Clarke PA, Workman P. Dual targeting of Hsc70 and Hsp72 inhibits Hsp90 function and induces tumor-specific apoptosis. Cancer Cell14(3),250–262 (2008).
  Medline CASGoogle Scholar
• 139  Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem. Res. Toxicol.19(3),376–381 (2006).
  Medline CASGoogle Scholar
• 201  Updated list of Hsp90 clients. www.picard.ch/downloads/downloads.html
  Google Scholar